Dual inhibition of HSP27 and FAO with ivermectin and perhexiline enhances the cytotoxic effect of cisplatin, serving as a promising therapeutic strategy for cisplatin-resistant ovarian cancer. This evidence concerns the gene HSPB1 and ovarian cancer.